Rev1 Ventures — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Clarametyx develops novel immune-enabling therapeutics targeting bacterial biofilms to modify disease progression in patients with chronic respiratory diseases.
BiotechHealthtechMedical DevicesColumbus, US
David Richards(Executive Officer)Peter G. Kleinhenz(Director)Michael Layman(Director)Chuck Bramlage(Director)Larry Edwards(Director)Michael Triplett II(Director)
Board seatWayne Embree· per SEC Form D
Co-investorsCincyTechJobsOhio VenturesOhio Innovation Fund
Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.
BiotechDigital HealthHealthtechMedical DevicesCary, US
Shahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)Julia Owens(Executive Officer, Director, Promoter)Richard Shea(Executive Officer, Director, Promoter)in
BoardHannah Chang(Director)Aiden Aceves(Director)in
Co-investorsARCH Venture PartnersInsight PartnersBroadview VenturesSolas BioVenturesRTW Investments L.P.
Myoptechs develops treatments and interventions for myopia, a progressive eye disease that causes worsening distance vision and can lead to sight-threatening complications.
HealthtechMedical DevicesColumbus, US
Paul Grimm(Executive Officer, Director)inBrad Beasecker(Executive Officer)in
BoardWayne Embree(Director)Robin Sears(Director)in
Co-investorsJobsOhio Ventures
Redi Health builds patient access and affordability programs that connect pharmaceutical manufacturers to patients through targeted approaches designed to increase medication adoption and sustained use.
Digital HealthHealthtechSaaS
Luke Buchanan(Founder)inJaimin Gandhi(Founder)in
Co-investorsMutual Capital PartnersBlue Heron CapitalM25Refinery Venture
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.